Current Trials



S1703 - (opened 4/2019): Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
NRG-BR007 DEBRA - (opened 8/2021): A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2- Negative, Oncotype Recurrence Score.
S2010 ASPEN - (opened 7/2023): A Randomized Phase III Trial comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in young Women with Stage I-III Breast.
S2212 SCARLET - (opened 10/2023): Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study.
EA3161 - (opened 02/2020): A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA.

ALCHEMIST Trials - (opened 8/2016):
  • A151216 (ALCHEMIST-Screen) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial.
  • E4512 (ALCHEMIST-ALK) Phase III Double-blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.
S2302 PRAGMATICA - (opened 7/2023): A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.
  • Connect Myeloid - (opened 6/2013): The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.
  • Connect MM - (opened 2010): Connect MM: The Multiple Myeloma Disease Registry.
Multiple Site
LP-CT-PALO - (opened 8/2022): A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy.


DAPA ACT HF - (opened 9/2020): Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure- Thrombolysis in Myocardial Infarction 68.
LIBREXIA - (opened 6/2023): Phase III Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.

For More Information: 
If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:
Watson Clinic Center for Research
1600 Lakeland Hills Blvd
Lakeland, FL 33805
Attn: Noreen McGowan, BSN, CCRC, Director
Phone 863-688-6826 · FAX 863-688-5842
Please indicate which of the following type(s) of information you would like:
  • Additional information about current protocols
  • Center for Research grants
  • Contributing to Center for Research funding
  • Involvement in Center for Research protocols

Return to Clinical Trials Page